There are 2789 resources available
801P - Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma
Presenter: Emeline Colomba
Session: ePoster Display
802P - A machine learning-based framework for efficacy and safety analysis of PD-1PD-L1 inhibitor application in gynaecological cancer on incomplete post-marketing surveillance dataset
Presenter: xiaomei Liu
Session: ePoster Display
803P - An histopathological algorithm to help the search for POLE mutated endometrial cancers
Presenter: Leslie Tessier
Session: ePoster Display
748P - Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Presenter: Margarita Romeo Marin
Session: ePoster Display
749P - Cardiotoxicity in patients treated with PARP-inhibitors
Presenter: Mariola Blanco Clemente
Session: ePoster Display
750P - Safety and efficacy of platinum desensitization treatment in patients with ovarian cancer and platinum hypersensitivity
Presenter: Simona Manacorda
Session: ePoster Display
751P - Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
Presenter: Pauline Corbaux
Session: ePoster Display
752P - PARP-inhibitors beyond progression: A new way to manage oligometastatic ovarian cancer recurrence
Presenter: Eleonora Palluzzi
Session: ePoster Display
753P - Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer
Presenter: Sandy Simon
Session: ePoster Display
730P - Anlotinib in patients with recurrent platinum-resistant or -refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study
Presenter: Huaying Wang
Session: ePoster Display